文献速递腹部CTMR

含脂肝细胞癌亚型的影像学与预后特征

Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes.
PubMed 文献 · Radiol Med · 2024-03-21

研究比较了病理证实的含脂肝细胞癌亚型(SH-HCC、SH-NOS-HCC、脂肪性NOS-HCC)的影像特征与预后。在NASH患者中,MRI无马赛克结构或CT显示肿块内脂肪对诊断SH-HCC特异性高(97.6%和97.7%)。各组无复发生存和总生存无差异。

要点

  • NASH患者中,MRI无马赛克结构或CT示肿块内脂肪对诊断SH-HCC特异性高(97.6%和97.7%)。
  • SH-HCC与SH-NOS-HCC的瘤内脂肪分数有差异(中位数9.5% vs 5%,p=0.03)。
  • 含脂肝细胞癌各亚型间的无复发生存和总生存无显著差异。

核心结论

  • 在NASH患者中,LR-4/LR-5且MRI无马赛克结构或CT示肿块内脂肪的病灶可提示SH-HCC;含脂肝细胞癌各亚型的肿瘤学结局似乎相似。

研究设计与样本

  • 研究类型为回顾性比较研究,纳入2012年9月至2021年6月间94例病理证实含脂肝细胞癌并接受肝切除的患者,采用LI-RADS v2018评估影像特征,化学位移MRI定量脂肪。

关键影像表现/征象

  • SH-HCC在MRI上马赛克结构罕见(7%),CT上肿块内脂肪更常显示(48%)。
  • 各组主要LI-RADS特征无差异,大多数肿瘤分类为LR-4/5。
  • 瘤内脂肪分数中位数为8%,SH-HCC与SH-NOS-HCC分别为9.5% vs 5%(p=0.03)。

诊断标准与关键数值

  • NASH合并MRI无马赛克结构诊断SH-HCC的特异度为97.6%。
  • NASH合并CT肿块内脂肪诊断SH-HCC的特异度为97.7%。

临床应用与阅片要点

  • 在NASH患者中,对LR-4/LR-5观察灶注意评估MRI马赛克结构和CT肿块内脂肪,以提示SH-HCC可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Steatohepatitic hepatocellular carcinoma (SH-HCC) is characterized by intratumoral fat with > 50% inflammatory changes. However, intratumoral fat (with or without inflammation) can also be found in not-otherwise specified HCC (NOS-HCC). We compared the imaging features and outcome of resected HCC containing fat on pathology including SH-HCC (> 50% steatohepatitic component), NOS-HCC with < 50% steatohepatitic component (SH-NOS-HCC), and fatty NOS-HCC (no steatohepatitic component).

MATERIAL AND METHODS: From September 2012 to June 2021, 94 patients underwent hepatic resection for fat-containing HCC on pathology. Imaging features and categories were assessed using LIRADS v2018. Fat quantification was performed on chemical-shift MRI. Recurrence-free and overall survival were estimated.

RESULTS: Twenty-one patients (26%) had nonalcoholic steatohepatitis (NASH). The median intra-tumoral fat fraction was 8%, with differences between SH-HCC and SH-NOS-HCC (9.5% vs. 5% p = 0.03). There was no difference in major LI-RADS features between all groups; most tumors were classified as LR-4/5. A mosaic architecture on MRI was rare (7%) in SH-HCC, a fat in mass on CT was more frequently depicted (48%) in SH-HCC. A combination of NASH with no mosaic architecture on MRI or NASH with fat in mass on CT yielded excellent specificity for diagnosing SH-HCC (97.6% and 97.7%, respectively). The median recurrence-free and overall survival were 58 and 87 months, with no difference between groups (p = 0.18 and p = 0.69).

CONCLUSION: In patients with NASH, an SH-HCC may be suspected in L4/LR-5 observations with no mosaic architecture at MRI or with fat in mass on CT. Oncological outcomes appear similar between fat-containing HCC subtypes.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Faure A, Dioguardi Burgio M, Cannella R, et al. Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes. Radiol Med. 2024. PMID: 38512627. doi:10.1007/s11547-024-01807-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。